Clinical Results of Intracoronary Brachytherapy (ICBT) for Multiple In-Stent Restenosis

Stadler, Peter F.; Schäfer, C.; Chaber, Silvia; Putnik, Kurt; Treutwein, Marius; Koelbl, Oliver; Muders, Frank

doi:10.1007/s00066-006-1488-x

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Controversially, the observational study BETA–WRIST showed ISR‐free survival rates of 66% after 6 months 10 with a substantial reduction of ISR‐free survival up to 54% after 2 years 11 . Three observational studies using brachytherapy for in‐stent restenosis have provided greater follow‐up data 12–14 . During a follow‐up of 3 years rates of MACE‐free survival ranged from 38% to 64%.…”

Section: Discussionmentioning

confidence: 99%

Intracoronary Beta‐Radiation Therapy for In‐stent Restenosis: Long‐Term Success Rate and Prediction of Failure

Vlachojannis

Fichtlscherer

Spyridopoulos

et al. 2010

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intracoronary Beta‐Radiation Therapy for In‐stent Restenosis: Long‐Term Success Rate and Prediction of Failure

Vlachojannis

Fichtlscherer

Spyridopoulos

et al. 2010

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…Thin struts have demonstrated decreased rates of restenosis compared to thicker struts. Brachytherapy or local radiation therapy so far has been highly successful in treating restenosis [56]. Oral drugs such as anti-platelet and anticoagulant agents, statins, and vitamins tested in order to prevent restenosis have failed to produce significant positive results.…”

Section: Potentialsmentioning

confidence: 98%

Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges

Paul¹,

ElHayek²,

Shum‐Tim³

et al. 2010

CDD

View full text Add to dashboard Cite

Percutaneous transvascular coronary angioplasty and stenting is one of the most commonly employed interventional procedures for the treatment of occlusive coronary artery disease. The common long-term complication of this treatment is re-stenosis occuring at the site of the atherosclerotic lesion following stenting. The rate of re-stenosis within 6 months could be as high as 20-30% of patients resulting in increased morbidity and tremendous costs to the health care system. The incidence has been somewhat reduced with the development of drug eluting stents, releasing drugs like paclitaxel, sirolimus, zotarolimus and everolimus with varied sustained release profiles. However the long-term benefits from large studies are still controversial and delayed onset of thrombosis is a major ongoing concern and lifelong anti-platelets therapy has been suggested clinically in patients bearing such pharmacological stents. Drug-eluting polymeric bioresorbable stent is being considered to hold immense promise to effectively address such pertinent complications mainly because of its improved biocompatibility, transient nature of supporting the intervened artery, eliminating local effect and damage of permanent metals, allowing smoother restoration of vasoreactivity and physiologic healing, and higher local drug delivery capacity in comparison to permanent metallic stents. In this article we review the current standpoint of drug eluting metallic stent, which has so long been considered as a major medical innovation in the field of pharmaceutical sciences, and its rapid evolution to pharmacological bioresorbable stent in order to promote proper vascular remodeling and achieve better risk-benefit ratio under diverse clinical challenges.

show abstract

“…in Form der stereotaktischen fraktionierten Strahlentherapie zur Behandlung kapillärer Hämangiome [13] oder im Rahmen der intrakoronaren Brachytherapie [10,33], kann die externe Radiotherapie als Langzeitnebenwirkung arterielle Stenosen induzieren [17]. Berichte in Lehrbüchern der Radioonkologie [24] und in der medizinischen Literatur betreffen vorwiegend Arterien im Kopf-Hals- [2,7] und Thoraxbereich [15,23,24], die Aorta [25] und die Iliakal-bzw.…”

Section: Introductionunclassified

Radiotherapieinduzierte Nierenarterienstenose nach Behandlung eines Ewing-Sarkoms

Tacconi

Bieri

2008

Strahlenther Onkol

View full text Add to dashboard Cite

Radiation-induced renal artery stenosis has only rarely been described in the literature, but arterial hypertension due to radiation-induced renal artery stenosis is a serious long-term sequela that can appear at a latency of up to 20 years after treatment. The paucity of reports presumably reflects the lesser frequency of radiotherapy for retroperitoneal tumors as compared to head-and-neck cancers, as well as lower awareness of the problem due to diagnostic bias in the era before CT and MRI were in routine use: at that time, carotid artery stenosis was easy to diagnose by ultrasonography, while radiation-induced renal artery stenosis, whose real incidence may well be higher, probably often went undetected. Thus, when a patient with a history of abdominal or retroperitoneal radiotherapy unexpectedly develops intractable hypertension, radiation-induced renal artery stenosis must be included in the differential diagnosis.

show abstract

Clinical Results of Intracoronary Brachytherapy (ICBT) for Multiple In-Stent Restenosis

Cited by 5 publications

References 25 publications

Intracoronary Beta‐Radiation Therapy for In‐stent Restenosis: Long‐Term Success Rate and Prediction of Failure

Intracoronary Beta‐Radiation Therapy for In‐stent Restenosis: Long‐Term Success Rate and Prediction of Failure

Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges

Radiotherapieinduzierte Nierenarterienstenose nach Behandlung eines Ewing-Sarkoms

Contact Info

Product

Resources

About